Anna Kwilas


Dr. Kwilas received her Ph.D. in Biomedical Science from The Ohio State University in 2010 with an emphasis in Molecular Virology & Gene Therapy and Translational Science. She performed her graduate research at The Research Institute at Nationwide Children’s Hospital examining the potential application of respiratory syncytial virus as a gene therapy vector for the treatment of cystic fibrosis.

Dr. Kwilas performed her post-doctoral research at the National Cancer Institute investigating the efficacy of modified vaccinia virus Ankara and adenovirus-based cancer vaccines alone and in combination with other approved and investigational cancer therapeutics.

Dr. Kwilas received the Interagency Oncology Task Force Fellowship in 2015. She began conducting research at FDA involving the generation of safer vector producing cells with the use of CRISPR/Cas9 genome editing technology and participating in gene therapy product CMC review. Since May 2016, Dr. Kwilas has been a full-time gene therapy CMC reviewer at the FDA.